Acknowledgements The authors thank the whole Obesity Research Unit team and especially the following colleagues for their contribution to this work: Elisa Silvennoinen (nutritionist), Tarja Hallaranta (study nurse)
The rivals are racing against each other to get an anti-obesity pill to market
Clinically, they showed a diffuse, non well-demarcated grey-brown pigmentation, mainly on the forehead, temples and cheeks [Figure - 1], [Figure - 2], [Figure - 3], [Figure - 4]
Its usually suitable for adults with a BMI of 30 and above, or 27 and above with a weight related condition, such as heart disease
Both cover PlexusDx GLP-1 medications fully
10.1038/s41581-018-0078-3 56 Kuro-oM.MatsumuraY.AizawaH.KawaguchiH.SugaT.UtsugiT.et al (1997)